GailLynn(Shaw)WrightMD

Oncology • Trinity, FL

Breast Cancer

Florida Cancer Specialists & Research Institute

Join to view full profile

Dr. Wright is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wright's full profile

Already have an account?

Office
Florida Cancer Specialists (TCN)
9320 State Road 54
Trinity, FL 34655
Phone+1 727-842-8411

Fax+1 727-847-2923
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1989
Duke University HospitalResidency, Internal Medicine, 1984 - 1986
University of North Carolina HospitalsInternship, Internal Medicine, 1983 - 1984
University of North Carolina at Chapel Hill School of MedicineClass of 1983

Certifications & Licensure

FL State Medical License 1996 - 2025
GA State Medical License 1999 - 2023
SC State Medical License 2001 - 2004
VA State Medical License 1987 - 2000
NC State Medical License 1984 - 2000
MD State Medical License 1988 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2014

Clinical Trials

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer Start of enrollment: 2017 Jun 20
Completed
Phase 2
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC Start of enrollment: 2017 Dec 21
Terminated
Phase 3
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer Start of enrollment: 2018 May 09
Completed
Phase 1
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC Start of enrollment: 2019 Jul 09
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

13 citations
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
Antoinette R Tan, Gail S Wright, Anu R Thummala, Michael A Danso, Lazar Popovic, Timothy J Pluard, Hyo S Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A Richards...> ;Clinical Cancer Research. 2022 Feb 15
19 citations
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with be...
Melissa M Hardesty, Thomas C Krivak, Gail S Wright, Erika Hamilton, Evelyn L Fleming, Jimmy Belotte, Erika K Keeton, Ping Wang, Divya Gupta, Aine Clements, Heidi J Gra...> ;Gynecologic Oncology. 2022 Aug 1
66 citations
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow...
C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark, J O'Shaughnessy, D Maag, M Untch, M Golshan, J Ponce Lorenzo, O Metzger, M Dunbar, W F Symmans, P Rastogi, J H Soh...> ;Annals of Oncology. 2022 Apr 1
302 citations
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectabl...
David Miles, Joseph Gligorov, Fabrice Andre, David Cameron, Andreas Schneeweiss, C. Barrios, B H Xu, A. Wardley, D. Kaen, L. Andrade, V. Semiglazov, M. Reinisch, Sheet...> ;Annals of Oncology. 2021 Jul 1
25 citations
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly L. Blackwell, Melinda L. Telli, Michelle E. Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cyn...> ;NPJ Breast Cancer. 2021 May 20
16 citations
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew M Wardley, Javier Cortes, Louise Provencher, Kathy D. Miller, A. Jo Chien, Hope S. Rugo, Joyce Steinberg, Jennifer Sugg, Iulia Cristina Tudor, M.T. Huizing, Rob...> ;Breast Cancer Research and Treatment. 2021 Feb 16
177 citations
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-R...> ;JAMA Oncology. 2021 Apr 1
63 citations
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso, Lazar Popovic, Timothy J. Pluard, Hyo S Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A. Richa...> ;The Lancet. Oncology. 2019 Nov 1
6 citations
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
Denise A. Yardley, Dianna Shipley, John D. Zubkus, Gail Lynn Shaw Wright, Patrick J. Ward, Aruna Mani, Mythili Shastry, L Finney, Laura M. DeBusk, John D. Hainsworth> ;Clinical Breast Cancer. 2019 Feb 1
474 citations
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright, Volkmar He...> ;The New England Journal of Medicine. 2018 Nov 29
8 citations
Cabazitaxel Plus Lapatinib as Therapy for HER2 + Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study
Denise A. Yardley, Lowell L. Hart, Patrick J. Ward, Gail Lynn Shaw Wright, Mythili Shastry, L Finney, Laura M. DeBusk, John D. Hainsworth> ;Clinical Breast Cancer. 2018 Oct 1
28 citations
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated...
Joyce O'Shaughnessy, Angela DeMichele, Cynthia X. Ma, Paul Richards, Denise A. Yardley, Gail S. Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan...> ;Breast Cancer Research and Treatment. 2018 Apr 19
68 citations
Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer:...
Daniel D. Karp, Sandra J. Lee, Steven M. Keller, Gail S. Wright, Seena C. Aisner, Steven A. Belinsky, David H. Johnson, Michael R. Johnston, Gary E. Goodman, Gerald H....> ;Journal of Clinical Oncology. 2013 Nov 20
26 citations
Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin- Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastat...
Andrew D. Seidman, Alison Conlin, Ariadne M. Bach, Mary Ellen Moynahan, Diana Lake, Andres Forero, G Wright, Mary Helen Hackney, Alicia Clawson, Larry Norton, Clifford...> ;Clinical Breast Cancer. 2013 Aug 1
141 citations
Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer
Craig W. Reynolds, Coleman K. Obasaju, Michael J. Schell, Xueli Li, Zhong Zheng, David Boulware, John R. Caton, Linda Cheryl DeMarco, Mark A. O'Rourke, Gail S. Wright,...> ;Journal of Clinical Oncology. 2009 Dec 1
2 citations
Potential biomarkers for the early detection of lung cancer.
Michael E. Gruidl, Gail L. Shaw Wright> ;Journal of Thoracic Imaging. 2000 Jan 1
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member
American College of Physicians - ACP
Fellow
American College of Chest Physicians - ACCP
Fellow
International Association for the Study of Lung Cancer - IASLC
Member

Hospital Affiliations

AdventHealth North PinellasTarpon Springs, Florida
Morton Plant North Bay HospitalNew Port Richey, Florida
HCA Florida Trinity HospitalNew Port Richey, Florida